Abstract

Recent reports have revealed myelodysplastic syndromes (MDS) to arise from cancer stem cells phenotypically similar to physiological hematopoietic stem cells. Myelodysplastic hematopoiesis maintains a hierarchical organization, but the proportion of several hematopoietic compartments is skewed and multiple surface markers are aberrantly expressed. These aberrant antigen expression patterns hold diagnostic and therapeutic promise. However, eradication of MDS requires targeting of early myelodysplasia propagating stem cells. This warrants an exact assessment of the differentiation stage at which aberrant expression occurs in transformed hematopoiesis. Here, we report results on the prospective and extensive dissection of the hematopoietic hierarchy in 20 patients with either low-risk MDS or MDS with excess blasts and compare it to hematopoiesis in patients with non-malignancy-associated cytopenia or B cell lymphoma without bone marrow infiltration. We found patients with MDS with excess blasts to exhibit characteristic expansions of specific immature progenitor compartments. We also identified the aberrant expression of several markers including ALDH, CLL-1, CD44, and CD47 to be specific features of hematopoiesis in MDS with excess blasts. We show that amongst these, aberrant CLL-1 expression manifested at the early uncommitted hematopoietic stem cell level, suggesting a potential role as a therapeutic target.

Highlights

  • Myelodysplastic syndromes (MDS) comprise a heterogeneous group of clonal hematopoietic disorders leading to ineffective hematopoiesis

  • This gating strategy allowed for the detection of aberrant immunophenotypes at distinct differentiation stages within the hematopoietic progenitor cell compartment and in CD34+ cells as a whole

  • Several studies have reported the aberrant expression of multiple antigens by cancer stem cells in acute myeloid leukemia (AML), including CLL-1, CD47, CD44, and aldehyde dehydrogenase (ALDH) [11,20,21,22]

Read more

Summary

Introduction

Myelodysplastic syndromes (MDS) comprise a heterogeneous group of clonal hematopoietic disorders leading to ineffective hematopoiesis. Recent reports have revealed the existence of MDS propagating stem cells [1,2,3,4,5]. While the hematopoietic hierarchy is conserved in MDS, hematopoietic stem and progenitor cell (HSPC) populations were shown to be skewed [2,4,5]. Cancer stem cells are suggested to initiate malignancies and to constitute a pool of quiescent cells that can hardly be eliminated by conventional therapy [3]. The elimination of cancer stem cells is deemed to be both essential and sufficient to eradicate.

Methods
Results
Conclusion
Full Text
Published version (Free)

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call